DNDi’s Corporate Documents | Neglected Diseases Background | Treatments developed by DNDi

By subscribing, you agree that all information submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive



DNDi’s Corporate Documents

Annual Report 2017  cover

2017 Annual Report

 2017 Financial Report

DNDi Brochure 2014

Browse Online
[Español] [Deutsch] [Français] [Português][العربي] [日本語]

DNDi Portfolio At-A-Glance Cover

DNDi Portfolio At A Glance 2016

Browse Online

DNDi Model Paper

DNDi Model Report

[English] [Deutsch] [Español] [Português]

DNDi Business Plan 2015-2023

DNDi Business Plan (2015-2023)


Neglected Diseases Background

Lancet Global Health - Fatal Imbalance 2 “The drug and vaccine landscape for neglected diseases(2000–11): a systematic assessment”
Lancet Global Health – 2013
PLoS - Ribeiro «Manifesto» for advancing the control and elimination of neglected tropical diseases”,
– 2010
Fatal Imbalance - 2001 “Fatal Imbalance”
Drugs for neglected diseases working group – 2001



ASAQ Malaria

Press release: “New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available”

ASMQ Malaria

Press release: “A Worldwide Public Partnership Makes Available a New, Once-a-Day Fixed-Dose Combination against Malaria”

NECT Sleeping Sickness

Press release: “Improved treatment for sleeping sickness now available”

Paediatric Benznidazole Chagas Disease

Press release: “New Child-Adapted Chagas Disease Treatment Approved for Registration” 

SSG&PM Visceral Leishmaniasis

Press release: “New treatment for kala azar, the most deadly parasitic disease after malaria”

Superbooster Therapy – Paediatric HIV/TB Paediatric HIV

Press release: “Study confirms key therapeutic advance for children living with HIV and tuberculosis”

Fexinidazole Sleeping Sickness

Press release: “European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness”